High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.

High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.

The optimal dose, scheme, and clinical setting for Ara-C in acute myeloid leukemia (AML) treatment remain uncertain. In this study, we performed a meta-analysis to systematically assess the impact of high-dose cytarabine (HDAC) on AML therapy during the induction and consolidation stages. Twenty-two...

Full description

Bibliographic Details
Main Authors:	Wei Li, Xiaoyuan Gong, Mingyuan Sun, Xingli Zhao, Benfa Gong, Hui Wei, Yingchang Mi, Jianxiang Wang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4192550?pdf=render

Similar Items

High-doses Granulocyte Colony-stimulating Factor (G-CSF) Benefit Elderly Patients with Acute Myeloid Leukemia
by: LI Wei, et al.
Published: (2018-05-01)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
by: Qiuyun Fang, et al.
Published: (2022-01-01)

Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
by: Hui Wei, et al.
Published: (2018-02-01)

Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells
by: Xiaoyuan Gong, et al.
Published: (2022-01-01)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
by: Amanda Lopes Maia Rodrigues, et al.
Published: (2020-07-01)

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia
by: Tuba Hilkay Karapınar, et al.
Published: (2012-03-01)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia.
by: Runxia Gu, et al.
Published: (2017-01-01)

High-dose cytarabine associated hemorrhagic pericardial effusion in a child with acute myeloid leukemia
by: Swati Kapoor, et al.
Published: (2020-06-01)

Posterior reversible encephalopathy syndrome after high dose cytarabine in pediatric acute myeloid leukemia
by: Gopila Gupta, et al.
Published: (2021-01-01)

CANDIDEMIA IN PATIENTS WITH ACUTE LEUKEMIA: ANALYSIS OF SEVEN YEARS’ EXPERIENCE AT A SINGLE CENTER IN
by: Xiaoyuan Gong, et al.
Published: (2020-01-01)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
by: Hui‐Jen Tsai, et al.
Published: (2021-05-01)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
by: Tomislav Smoljo, et al.
Published: (2023-10-01)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
by: Rebecca Anderson, et al.
Published: (2022-03-01)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
by: Guangji Zhang, et al.
Published: (2022-04-01)

P543: CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: Rithin Nedumannil, et al.
Published: (2023-08-01)

"Time sequential high dose of Cytarabine in acute myelocytic leukemia "
by: Ghavamzadeh A, et al.
Published: (2003-03-01)

"Time sequential high dose of Cytarabine in acute myelocytic leukemia "
by: Ghavamzadeh A, et al.
Published: (2003-05-01)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
by: Jean Galtier, et al.
Published: (2021-11-01)

Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
by: Sarah M Leonard, et al.
Published: (2014-01-01)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
by: Huali Sun MD, et al.
Published: (2023-10-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
by: Jing Wang, et al.
Published: (2013-01-01)

A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia
by: Yang Song, et al.
Published: (2022-12-01)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
by: M.C. Azevedo, et al.
Published: (2015-02-01)

Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine
by: Panfilova Hanna, et al.
Published: (2021-01-01)

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
by: Wei Guoqing, et al.
Published: (2011-11-01)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
by: Nienke Visser, et al.
Published: (2021-02-01)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
by: Nizar Serhan, et al.
Published: (2020-06-01)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
by: Qingguo Liu, et al.
Published: (2020-07-01)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
by: Sook-Kyoung Heo, et al.
Published: (2020-12-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
by: Linyu Yuan, et al.
Published: (2023-08-01)

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
by: Cortes, JE, et al.
Published: (2020)

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
by: Yan-Yan Li, et al.
Published: (2024-01-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia
by: Tao Zhang, et al.
Published: (2024-01-01)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
by: Gabriela Rodríguez-Macías, et al.
Published: (2023-06-01)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
by: Sonali P. Barwe, et al.
Published: (2022-02-01)

Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling
by: Qiong Su, et al.
Published: (2023-12-01)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
by: Stefan Hatzl, et al.
Published: (2020-02-01)